Synovics Pharmaceuticals, Inc.
Synovics Pharmaceuticals, Inc.
Your view on SYVC
Overview
What the company does, where it operates, and who runs it.
About Synovics Pharmaceuticals, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- John R. Palmer
- Headquarters
- 5360 Northwest 35th Avenue, Fort Lauderdale, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- John R. Palmer
- Headquarters
- 5360 Northwest 35th Avenue, Fort Lauderdale, US
Synovics Pharmaceuticals, Inc., through its subsidiaries, engages in the development, manufacture, and commercialization of generic over-the-counter (OTC) pharmaceutical products and generic prescription drug products primarily in the United States.
The company's OTC product categories include analgesics, cough, cold, antihistamines, asthma relief, and laxatives. It packages and distributes its products to chain drug stores, wholesalers, and distributors in the United States. The company was formerly known as Bionutrics Inc. and changed its name to Synovics Pharmaceuticals, Inc. in 2006.
Synovics Pharmaceuticals, Inc. was founded in 1983 and is based in Fort Lauderdale, Florida. Synovics Pharmaceuticals, Inc. operates as a subsidiary of Maneesh Pharmaceuticals Limited.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Synovics Pharmaceuticals, Inc., and the rating behind it. SYVC last traded at $0.0001; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Synovics Pharmaceuticals, Inc.. Starting points for Synovics Pharmaceuticals, Inc.: EPS -$0.17, beta 83.17 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Synovics Pharmaceuticals, Inc.. Synovics Pharmaceuticals, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Synovics Pharmaceuticals, Inc.. Trailing twelve-month EPS for Synovics Pharmaceuticals, Inc. stands at -$0.17. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Synovics Pharmaceuticals, Inc.. Synovics Pharmaceuticals, Inc. has reported as a listed company since 2023. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Synovics Pharmaceuticals, Inc. valued side by side against its closest peers. Synovics Pharmaceuticals, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Synovics Pharmaceuticals, Inc., and how their positions are changing. At a $2,983 market value, institutional positions materially move Synovics Pharmaceuticals, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Synovics Pharmaceuticals, Inc. executives and directors. Shares of Synovics Pharmaceuticals, Inc. have traded between $0.0001 and $0.0001 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Synovics Pharmaceuticals, Inc.. Synovics Pharmaceuticals, Inc. is a $2,983 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Synovics Pharmaceuticals, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Synovics Pharmaceuticals, Inc.. Coverage tracks Synovics Pharmaceuticals, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.